Positive Buy Rating for Arcus Biosciences Driven by Promising Trial Developments and Strategic Outlook

H.C. Wainwright analyst Emily Bodnar has maintained their bullish stance on RCUS stock, giving a Buy rating today.

Emily Bodnar’s rating is based on several promising developments within Arcus Biosciences. The initiation of the PEAK-1 trial, which evaluates the combination of casdatifan and cabozantinib in patients with advanced renal cell carcinoma, is a significant factor. Initial data presented at ASCO demonstrated a synergistic effect of the combination, showing higher response rates compared to either agent alone, without additional toxicity. This trial’s design and early results suggest a positive outlook for the treatment’s efficacy.
Furthermore, Arcus Biosciences is expected to release more mature data from the ARC-20 study throughout 2025, which includes various cohorts testing different dosages and combinations of casdatifan. The anticipation of these results, particularly in the context of the company’s strategic targeting of similar patient populations in Phase 3 trials, supports a favorable view of the company’s potential. These factors collectively contribute to Emily Bodnar’s Buy rating for Arcus Biosciences.

According to TipRanks, Bodnar is an analyst with an average return of -2.5% and a 30.33% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as Agenus, Agios Pharma, and NovoCure.

In another report released today, Barclays also maintained a Buy rating on the stock with a $14.00 price target.